Skip to main content
. 2021 Aug;32(8):2020–2030. doi: 10.1681/ASN.2020101531

Table 3.

HR for all-cause mortality and MACE by ferritin level, with progressive covariate adjustment

Outcome Ferritin (ng/ml) N (%) Hazard Ratios (95% CIs)
Model 1 Model 2 Model 3 Model 4 Model 5
All-cause mortality <50 777 (15) 1.17 (0.94 to 1.45) 1.21 (0.96 to 1.52) 1.14 (0.91 to 1.43) 0.97 (0.75 to 1.26) 0.99 (0.76 to 1.28)
50–99 1201 (23) 1.00 (0.80 to 1.24) 1.02 (0.81 to 1.28) 1.01 (0.80 to 1.28) 0.96 (0.75 to 1.22) 0.97 (0.76 to 1.24)
100–299 2236 (43) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
≥300 931 (18) 1.37 (1.10 to 1.70) 1.29 (1.03 to 1.61) 1.22 (0.98 to 1.53) 1.26 (1.00 to 1.59) 1.21 (0.96 to 1.53)
MACE <50 431 (14) 1.19 (0.83 to 1.68) 1.18 (0.82 to 1.70) 1.10 (0.78 to 1.56) 0.92 (0.63 to 1.34) 0.94 (0.65 to 1.36)
50–99 707 (23) 1.01 (0.76 to 1.33) 1.03 (0.77 to 1.39) 0.97 (0.72 to 1.30) 0.91 (0.67 to 1.26) 0.94 (0.70 to 1.27)
100–299 1346 (45) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
≥300 532 (18) 1.13 (0.85 to 1.49) 1.12 (0.85 to 1.48) 1.01 (0.75 to 1.36) 1.11 (0.84 to 1.47) 1.06 (0.80 to 1.42)

For all-cause death, the sample includes patients from Brazil, France, Germany, and the United States. For MACE, the sample includes patients from Brazil, France, and the United States. Progressive adjustments: Model 1: Unadjusted. Model 2: Country, age, sex, Black race, body mass index (BMI), eGFR and albuminuria. Model 3: + ESA use and 11 summary comorbidities. Model 4: + serum albumin, white blood cell count, and TSAT. Model 5: + Hgb.